#ASCO22: As it dodges a takeover bid, Zymeworks wants what Daiichi Sankyo got: a massive Big Pharma partner
CHICAGO — The Daiichi Sankyo story made waves Sunday at the annual ASCO meeting in Chicago, as Enhertu potentially disrupted the breast cancer landscape by adding HER2-low to the dictionary, and Zymeworks wants to follow in their footsteps.
Specifically, the struggling biotech — which recently hired a new CEO, replaced most of the C-suite, laid off staff and rejected a hostile takeover bid — wants a global partner just like Daiichi got in its $6 billion 2019 deal with AstraZeneca to help turn Enhertu into what it is today.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.